Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma

Hedblad, Mari‐Anne; Mallbris, Lotus

doi:10.1016/j.jaad.2011.06.029

Cited by 59 publications

(48 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hedblad et al recently reported a complete clearance rate of 83% using grenz-rays as primary treatment for LM and early LMM. Clearance rate for LM and LMM treated with grenz-rays plus partial excision was 90% [55]. One review article including 349 patients with LM/ LMM treated with a variety of regimens of radiotherapy showed a 5% recurrence rate.…”

Section: • • Medical Managementmentioning

confidence: 99%

Lentigo Maligna and Lentigo Maligna Melanoma: Contemporary Issues in Diagnosis and Management

2015

View full text Add to dashboard Cite

Lentigo maligna and lentigo maligna melanomas present diagnostic and treatment dilemmas due to their frequent presence within a background of sun-damaged skin, and their location on cosmetically and functionally sensitive areas. As the incidence of this entity is increasing, diagnostic and management controversies have developed. While surgery remains the gold standard of treatment, nonsurgical treatment options are also emerging for both adjunctive and primary therapy.

show abstract

Section: • • Medical Managementmentioning

confidence: 99%

Lentigo Maligna and Lentigo Maligna Melanoma: Contemporary Issues in Diagnosis and Management

2015

View full text Add to dashboard Cite

show abstract

“…Treatment tolerability in RT with grenz and soft X-rays is good as the therapy-induced acute radiodermatitis occurs only within the treated site and heals within 4–6 weeks after completion of treatment [27, 28, 36]. In our cohort, neither grade > 3 adverse events nor major disfigurement occurred.…”

Section: Discussionmentioning

confidence: 85%

“…Interestingly, all of the recurrent lesions were located on the face. Another study on LM and early LM melanoma by Hedblad and Mallbris [36] evaluated the efficacy of grenz rays and reported a residual lesion in 15 and recurrence in 58 out of 593 lesions, 73% of which relapsed within 24 months after the end of treatment. This is consistent with our data (70% of recurrences within 24 months, however in our cohort a smaller percentage in the group of melanocytic lesions) and emphasizes the importance of follow-up for at least 2 years after the end of treatment.…”

Section: Discussionmentioning

confidence: 99%

Radiotherapy in Periocular Cutaneous Malignancies: A Retrospective Study

et al. 2019

View full text Add to dashboard Cite

Background: Due to the importance of function and cosmetics, periocular skin malignancies represent a therapeutic challenge. Objective: To evaluate the safety and efficacy of radiotherapy (RT) treating periocular skin tumors. Methods: Data of patients with periocular tumors treated with grenz or soft X-rays at the University Hospital Zurich, Switzerland, between 2009 and 2014 were reviewed. Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with associated in situ lesions, cutaneous melanoma, lentigo maligna (LM), cutaneous lymphoma and Kaposi’s sarcoma were included in the analysis. Results: We found 159 periocular lesions in 145 patients. Overall recurrence was highest for actinic keratosis and Bowen’s disease (27%), melanoma (17%) and LM (15%), whereas SCC and BCC showed recurrence in 11 and 10%, respectively. 45% of all recurrences occurred within 12 months after treatment, with a median time to recurrence of 13 months (range 3–73). Conclusion: RT, which provides a good therapeutic response with minimal adverse events, is a therapy option for periocular cutaneous malignancies.

show abstract

“…13 There is a more recent retrospective study of 593 patients from Sweden where 593 patients were treated with RT (as definitive therapy in 350 patients, adjuvant RT after partial excision in 71 patients, and adjuvant RT after radical surgery in 172 patients) for 20 years. 15 Most of the patients had more than 2 years of follow-up. The reported response rate was 88%, and most of the recurrence occurred within the 2 years.…”

Section: Lentigo Maligna and Lentigo Maligna Melanomamentioning

confidence: 99%

Role of Radiation Therapy in Cutaneous Melanoma

Hong¹,

Fogarty²

2012

The Cancer Journal

View full text Add to dashboard Cite

Radiotherapy plays a vital role in the management of primary cutaneous melanoma in definitive, adjuvant, and palliative settings. The indications for radiation therapy in melanoma are expanding on the basis of recent clinical trials. The advances of technology in delivering radiation therapy (stereotactic radiosurgery for brain metastasis, stereotactic body radiation therapy, and intensity-modulated radiation therapy) and an increasing appreciation of melanoma radiobiology in particular mean that the role of radiation therapy will continue to expand in this disease.

show abstract

Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma

Cited by 59 publications

References 41 publications

Lentigo Maligna and Lentigo Maligna Melanoma: Contemporary Issues in Diagnosis and Management

Lentigo Maligna and Lentigo Maligna Melanoma: Contemporary Issues in Diagnosis and Management

Radiotherapy in Periocular Cutaneous Malignancies: A Retrospective Study

Role of Radiation Therapy in Cutaneous Melanoma

Contact Info

Product

Resources

About